

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number  
**WO 01/82949 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 38/22 //**  
(A61K 38/22, 31:00) (A61K 38/22, 33:00) (A61K 38/22, 38:00)
- (21) International Application Number: **PCT/US01/12696**
- (22) International Filing Date: **19 April 2001 (19.04.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**09/561,917** **1 May 2000 (01.05.2000)** **US**
- (71) Applicant: **SCICLONE PHARMACEUTICALS, INC.**  
[US/US]; 901 Mariners Island Boulevard, San Mateo, CA 94404 (US).
- (72) Inventors: **RUDOLPH, Alfred, R.**; 14142 Liddicoat Drive, Los Altos Hills, CA 94022 (US). **TAM, Vincent, Chung-Yin**; 35, Ventris Road, Happy Valley, Hong Kong (CN). **QUAN, Maggie, Jie**; Room 502, No. 16, Lane 336, E Mei Road, Shanghai 200080 (CN).
- (74) Agents: **REPPER, George, R.** et al.; Rothwell, Figg, Ernst & Manbeck, P.C., Suite 701-E, 555 13th Street, N.W., Washington, DC 20004 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 01/82949 A2**

(54) Title: **METHOD OF REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS**

(57) Abstract: A method for reducing the severity of chemotherapy side effects in cancer patients by administering thymosin  $\alpha_1$  in conjunction with the administration of a chemotherapy agent to the patient. As a result of the reduction of post-chemotherapy side effects, patients experience an increase in the quality of life.

**METHOD OF REDUCING SIDE EFFECTS OF  
CHEMOTHERAPY IN CANCER PATIENTS**

**FIELD OF THE INVENTION**

5           The present invention relates to improved treatment of cancer in animals, including humans, by reducing the side effects of chemotherapy.

**BACKGROUND OF THE INVENTION**

Cancers are a leading cause of death in animals and humans. The leading cancer  
10   therapies today are surgery, radiation and chemotherapy. In spite of advances in the field of cancer treatment, each of these known therapies has serious side effects. For example; surgery disfigures the patient or interferes with normal bodily functions. Chemotherapy or radiation therapies cause patients to experience acute debilitating symptoms including nausea, vomiting, diarrhea, hypersensitivity to light, hair loss, etc. The side effects of these cytotoxic compounds  
15   frequently limit the frequency and dosage at which they can be administered.

Chemotherapeutic agents have been found useful in treating cancer in humans. Broadly classified as antineoplastics, chemotherapeutic agents found to be of assistance in the suppression of tumors include but are not limited to alkylating agents (e.g., nitrogen mustards), antimetabolites (e.g., pyrimidine analogs), radioactive isotopes (e.g., phosphorous and iodine),  
20   hormones (e.g., estrogens and adrenocorticosteroids), miscellaneous agents (e.g., substituted ureas) and natural products (e.g., vinca alkyloids and antibiotics). Although the preceding compounds are not curative agents, they are widely recognized in the medical profession as useful in the suppression, palliation, retardation and control of malignant tumors. While these compounds have been found to be effective and are in general clinical use as antiproliferative  
25   agents, there are well recognized drawbacks associated with their administration. The alkylating agents have marked cytotoxic action and the ability of these drugs to interfere with normal mitosis and cell division can be lethal. The antimetabolites can lead to anorexia, progressive weight loss, depression, and coma. Prolonged administration of antimetabolites can result in serious changes in bone marrow. Both the alkylating agents and the antimetabolites generally  
30   have a depressive effect on the immunosuppressive system. Prolonged administration of natural products such as vinca alkyloids can also result in bone marrow depression. Hydroxy urea and other chemically derived agents can lead to rapid reduction in levels of adrenocorticosteroids and their metabolites. The administration of hormonal compounds or radioactive isotopes is also

undesirable from the viewpoint of inflicting damage on the immunosuppressive system and thereby disabling the body's defenses against common infections. In most instances, it would be preferable to employ a chemotherapeutic agent which is effective in controlling, retarding, or suppressing the growth of malignant tumors while simultaneously acting to stimulate the patient's  
5 immune system.

## SUMMARY OF THE INVENTION

In accordance with the present invention, a method is provided in which the side effects of chemotherapy in cancer patients are reduced by administering thymosin  $\alpha_1$  ("T $\alpha_1$ ") in  
10 conjunction with the administration of the chemotherapy agent to the patient. The reduction in the severity of post-chemotherapy side effects increases the quality of life experienced by patients receiving chemotherapy.

## DETAILED DESCRIPTION OF THE INVENTION

15 It is known that the thymus produces a family of polypeptides termed thymosin and perhaps several other thymic hormones and/or factors which play an important role in the maturation, differentiation and function of T-cells. Thymosin has been found to induce T-cell differentiation and enhance immunological functions in genetically athymic mice, in adult thymectomized mice and in NZB mice with severe autoimmune reactions, in tumor bearing mice  
20 and in mice with casein-induced amyloidosis.

Thymosin  $\alpha_1$ , an acidic polypeptide isolated from thymosin fraction 5 is an immunomodulator that acts primarily by enhancing T-cell function and also has been shown to have direct anti-cancer effects. Thymosin  $\alpha_1$  has been found to stimulate T-cell maturation, differentiation and function.

25 It has been previously documented that thymosin  $\alpha_1$  reduces the incidence and severity of post-chemotherapy infections. It has now been found that the use of thymosin  $\alpha_1$  in conjunction with the administration of antineoplastics (chemotherapeutic agents) significantly improves the cancer patient's quality of life by reducing nausea, vomiting, loss of appetite, inability to sleep, decline in overall feeling, reduction in daily activity, fatigue and depression. The administration  
30 of thymosin  $\alpha_1$  does not appear to result in any side effects.

The mechanism by which thymosin  $\alpha_1$  acts to improve the patient quality of life is not yet known. Without being bound to any particular theory, one possibility may relate to the apparent ability of thymosin  $\alpha_1$  to block neurotransmitter receptors. It is believed that most

chemotherapeutic agents activate the chemoreceptor trigger zone (CTZ) and that the CTZ chemotherapy interaction triggers the release of neurotransmitters that activate the vomiting center. CTZ neurotransmitters that are thought to cause emesis include but are not limited to, dopamine, serotonin, histamine, norepinephrine, apomorphine, neurotensin, vasoactive intestinal polypeptide (VIP). In vitro and in vivo studies, have shown that thymosin  $\alpha_1$  has a VIP receptor blocking effect. This may explain why thymosin  $\alpha_1$  can control vomiting in patients whose vomiting could not be controlled by 5-HT blockers.

The increase in quality of life may be due to thymosin  $\alpha_1$ 's ability to control GI adverse effects like nausea and vomiting through the above described VIP receptor blocking effect or it could be the result of a reduction of low grade, clinically undetectable infections or some combination thereof.

In one embodiment of the present invention, the thymosin  $\alpha_1$  is administered prior to the administration of the chemotherapy. The thymosin  $\alpha_1$  may be administered on a single day or be administered on several days prior to the chemotherapy.

In another embodiment of the invention, the thymosin  $\alpha_1$  is administered following the administration of the antineoplastic agent. In this embodiment, the thymosin  $\alpha_1$  may be administered once or several times prior to the chemotherapy. This administration may take place on a single day or on a series of days prior to the administration of the antineoplastic agent.

In another embodiment of the invention, thymosin  $\alpha_1$  is administered prior to and subsequent to the administration of the antineoplastic agent. This administration may take place on one or multiple days prior to and one or multiple days subsequent to the chemotherapy.

In one preferred embodiment, thymosin  $\alpha_1$  is administered to cancer patients once each day on four days immediately preceding the administration of the antineoplastic agent and once on day 2 and on day 4 following chemotherapy.

$T\alpha_1$  can be administered in any suitable way, such as by injection, infusion, or transcutaneously. Other methods of administration may also be possible, such as orally as a liquid or solid dosage form. In preferred embodiments  $T\alpha_1$  is injected.

Thymosin  $\alpha_1$  may be administered at any suitable dosage level, e.g., within a range of about 0.1 - 3 mg. In preferred embodiments, thymosin  $\alpha_1$  is administered via injection at a dosage of about 1.6 mg s.c.

Thymosin  $\alpha_1$  can be administered to reduce side effects of any suitable antineoplastic agents, including one or more antineoplastic agent selected from the group consisting of alkylating agents (e.g., nitrogen mustards), antimetabolites (e.g., pyrimidine analogs), radioactive

isotopes (e.g., phosphorous and iodine), hormones (e.g., estrogens and adrenocorticosteroids), miscellaneous agents (e.g., substituted ureas) and natural products (e.g., vinca alkyloids and antibiotics). Examples of such antineoplastic agents include but are not limited to the following:

5 ADJUNCT ANTINEOPLASIC THERAPY:

- Aloprim™ for Injection
- Anzemet® Injection
- Anzemet® Tablets
- Aredia® for Injection
- 10 Didronel® I.V. Infusion
- Diflucan® Tablets, Injection, and Oral Suspension
- Epogen® for Injection
- Ergamisol® Tablets
- Ethyol® for Injection
- 15 Kytril® Injection
- Kytril® Tablets
- Leucovorin Calcium for Injection
- Leucovorin Calcium Tablets
- Leukine®
- 20 Marinol® Capsules
- Mesnex® Injection
- Neupogen® for Injection
- Procrit® for Injection
- Saiagen® Tablets
- 25 Sandostatin® Injection
- Zinecard® for Injection
- Zofran® Injection
- Zofran® ODT™ Orally Disintegrating Tablets
- Zofran® Oral Solution
- 30 Zofran® Tablets
- Zyloprim® Tablets

ALKYLATING AGENTS:

- Myleran® Tablets

Paraplatin® for Injection

Platinol® for Injection

Platinol-AQ® Injection

Thioplex® for Injection

5 NITROGEN MUSTARDS:

Alkeran® for Injection

Alkeran® Tablets

Cytosan® for Injection

Cytosan® Tablets

10 Ifex® for Injection

Leukeran® Tablets

Mustargen® for Injection

NITROSOUREAS:

BiCNU®

15 CeeNU®

Gliadel® Wafer

Zanosar® Sterile Powder

ANTIBIOTICS:

Adriamycin® PFS/RDS for Injection

20 Blenoxane®

Cerubidine® for Injection

Cosmegen® for Injection

DaunoXome®

Doxil® Injection

25 Doxorubicin Hydrochloride for Injection, USP

Idamycin PFS Injection

Mithracin® for Intravenous Use

Mutamycin® for Injection

Nipent® for Injection

30 Novantrone® for Injection

Rubex® for Injection

Valstar™ Sterile Solution for Intravesical Instillation

Lupron® Injection

Zoladex®

#### PROGESTINS

Depo-Provera® Sterile Aqueous Suspension

5 Megace® Tablets

#### IMMUNOMODULATORS

Ergamisol® Tablets

Proleukin® for Injection

#### MISCELLANEOUS ANTINEOPLASTICS

10 Camptosar® Injection

Celestone® Soluspan® Suspension

DTIC-Dome®

Elspar® for Injection

Etopophos® for Injection

15 Etoposide Injection

Gemzar® for Injection

Herceptin® I.V.

Hexalen® Capsules

Hycamtin® for Injection

20 Hydrea® Capsules

Hydroxyurea Capsules, USP

Intron® A for Injection

Lysodren® Tablets

Matulane® Capsules

25 Navelbine® Injection

Oncapsar®

Oncovin® Solution Vials and Hyporets

Ontak™ Vials

Proleukin® for Injection

30 Rituxan™ for Infusion

Rituxan® I.V.

Roferon®-A Injection

Taxol® Injection

Taxotere® for Injection Concentrate

TheraCys®

Tice® BCG Vaccine, USP

Velban® Vials

5 VePesid® Capsules

VePesid® for Injection

Vesanoid® Capsules

Vumon® for Injection

#### PHOTOSENSITIZING AGENTS

10 Photofrin® for Injection

#### SKIN AND MUCUS MEMBRANE AGENTS

Efudex® Cream

Efudex® Topical Solution

Fluoroplex® Topical Cream

15 Fluoroplex® Topical Solution

The invention is illustrated by the following Example, which is not intended to be limiting.

#### Example 1

20 METHOD: A randomized crossover open label trial was performed. A total of sixty patients, twenty with lung cancer, twenty with gastric cancer and twenty with breast cancer were studied during two complete cycles of chemotherapy. All patients were randomized into two groups. In group 1, patients received chemotherapy with thymosin  $\alpha_1$  in the first cycle, and without thymosin  $\alpha_1$  in the second cycle. While patients in group 2 received chemotherapy without  
25 thymosin  $\alpha_1$  in the first cycle, and with thymosin  $\alpha_1$  in the second cycle. The patients were treated as follows:

Twenty lung cancer patients were treated with 100 mg of Etoposide IV on days 1-5 and 40 mg of Cisplatin I.V. on days 1-3 in a 21 day cycle.

Twenty gastric cancer patients were treated with 100 mg of Etoposide IV on days 1-5,  
30 30 mg/m<sup>2</sup> Calcium Leucovorin I.V. on days 1-5 and 500 mg/m<sup>2</sup> 5-Fluorouracil (5-FU) I.V. on days 1-5.

Twenty breast cancer patients were treated with 5-Fluorouracil 500 mg/m<sup>2</sup>, Adriamycin I.V. 30 mg/m<sup>2</sup> I.V. on day 1 and cyclophosphamide 500 mg/m<sup>2</sup> I.V. on day 1.



A mild anti-emetic consisting of 20 mg metoclopramide, I.M. and 5 mg Dexamethasone I.V. were given to all patients on days 1-5. All subjects on thymosin received six injections of 1.6 mg s.c.  $T\alpha_1$  on each of the four days immediately preceding the chemotherapy and on days two and four following chemotherapy. All patients who have completed the two cycles of chemotherapy, then were reallocated into two cohorts, A and B. Cohort A are patients with  $T\alpha_1$ , and Cohort B are patients without  $T\alpha_1$ .

ANALYSIS: Quality of life was analyzed using a scored scale for (1) loss of appetite, (2) loss of sleep, (3) fatigue, (4) reduction in daily activity, (5) decline in overall feeling, (6) depression and (7) nausea and vomiting. Maximum total score was 35 points.

RESULTS: A comparison between cycles (with  $T\alpha_1$  and without  $T\alpha_1$ ) was performed. The addition of  $T\alpha_1$  to chemotherapy cycles significantly increases the quality of life scores compared with cycles without  $T\alpha_1$ .

#### Side Effects

	Loss of Appetite	4.33 vs. 3.99	p = 0.0001
15	Loss of Sleep	4.41 vs. 4.10	p = 0.002
	Fatigue	4.05 vs. 3.70	p = 0.0001
	Reduction in Daily Activity	4.12 vs. 3.84	p = 0.0001
	Decline in Overall Feeling	4.32 vs. 3.94	p = 0.0001
	Depression	4.01 vs. 3.72	p = 0.003
20	Nausea and Vomiting	4.29 vs. 3.93	p = 0.001

Nausea and vomiting classified according to WHO criteria:

Group	n	Grade 0	Gr.1	Gr.2	Gr.3	Gr.4	P value
-----	--	-----	----	----	----	----	-----
A (with $T\alpha_1$ )	54	7/55	33	13	1	0	P<0.0005
25 B (Without $T\alpha_1$ )	53	4/53	19	19	11	0	

CONCLUSION: Adding  $T\alpha_1$  to chemotherapy significantly improves patient quality of life.

CLAIMS

1. A method of reducing side effects of chemotherapy in a cancer patient, comprising administering to a cancer patient thymosin  $\alpha_1$  ( $T\alpha_1$ ) in conjunction with administration of a chemotherapy agent to said patient.

5

2. The method of claim 1 wherein the  $T\alpha_1$  is administered prior to administration of said chemotherapy agent.

3. The method of claim 1 wherein said  $T\alpha_1$  is administered subsequent to said  
10 chemotherapy agent.

4. The method of claim 1 wherein said  $T\alpha_1$  is administered both prior to and subsequent to said chemotherapy agent.

15 5. The method of claim 2 wherein said  $T\alpha_1$  is administered during a plurality of administrations on a plurality of days prior to said chemotherapy agent.

6. The method of claim 2 wherein said  $T\alpha_1$  is administered as a single administration on each of a plurality of days prior to said chemotherapy agent.

20

7. The method of claim 2 wherein a single administration of  $T\alpha_1$  is administered one day immediately prior to administration of said chemotherapy agent.

8. The method of claim 2 wherein a single administration of  $T\alpha_1$  is administered on  
25 each of two days immediately prior to administration of said chemotherapy agent.

9. The method of claim 2 wherein a single administration of  $T\alpha_1$  is administered on each of three days immediately prior to administration of said chemotherapy agent.

30 10. The method of claim 2 wherein a single administration of  $T\alpha_1$  is administered on each of four days immediately prior to administration of said chemotherapy agent.

11. The method of claim 3 wherein a plurality of administrations of said  $T\alpha_1$  are administered on a plurality of days subsequent to administration of said chemotherapy agent.

12. The method of claim 3 wherein a single administration of  $T\alpha_1$  is administered on each of a plurality of days subsequent to administration of said chemotherapy agent.

13. The method of claim 3 wherein a single administration of  $T\alpha_1$  is administered one day immediately subsequent to administration of said chemotherapy agent.

14. The method of claim 3 wherein a single administration of  $T\alpha_1$  is administered on each of two days immediately subsequent to said administration of said chemotherapy agent.

15. The method of claim 4 wherein a plurality of administrations of said  $T\alpha_1$  are administered on a plurality of days prior to and subsequent to the administration of said chemotherapy agent.

16. The method of claim 4 wherein a single administration of  $T\alpha_1$  is administered on each of a plurality of days prior to and subsequent to the administration of said chemotherapy agent.

17. The method of claim 4 wherein a single administration of  $T\alpha_1$  is administered one day immediately prior to and one day immediately subsequent to administration of said chemotherapy agent.

18. The method of claim 4 wherein a single administration of  $T\alpha_1$  is administered on each of two days immediately days prior to and two days immediately subsequent to the administration of said chemotherapy agent.

19. The method of claim 1 wherein  $T\alpha_1$  is administered at a dosage within a range of about .1 - 3.2 mg.

20. The method of claim 1 wherein  $T\alpha_1$  is administered at a dosage of about 1.6 mg.

21. The method of claim 1 wherein said chemotherapy agent is selected from the group consisting of antineoplastic alkylating agents, antineoplastic antimetabolites, antineoplastic radioactive isotopes, antineoplastic hormones, antineoplastic ureas, antineoplastic vinca alkaloids, antineoplastic antibiotics, and combinations thereof.

5

22. The method of claim 21 wherein said antineoplastic alkylating agents are nitrogen mustards, said antineoplastic antimetabolites are pyrimidine analogs, said antineoplastic radioactive isotopes are radioactive phosphorous, radioactive iodine or a combination thereof, and said antineoplastic hormones are estrogens, adrenocorticosteroids, and combinations thereof.

10

23. The method of claim 1 wherein said chemotherapy agent is selected from the group consisting of: allopurinol sodium, dolasetron mesylate, pamidronate disodium, etidronate, fluconazole, epoetin alfa, levamisole HCl, amifostine, granisetron HCl, leucovorin calcium, sargramostim, dronabinol, mesna, filgrastim, pilocarpine HCl, octreotide acetate, dexrazoxane, ondansetron HCl, ondansetron, busulfan, carboplatin, cisplatin, thiotepa, melphalan HCl, melphalan, cyclophosphamide, ifosfamide, chlorambucil, mechlorethamine HCl, carmustine, lomustine, polifeprosan 20 with carmustine implant, streptozocin, doxorubicin HCl, bleomycin sulfate, daunirubicin HCl, dactinomycin, daunorubicin citrate, idarubicin HCl, plimycin, mitomycin, pentostatin, mitoxantrone, valrubicin, cytarabine, fludarabine phosphate, floxuridine, cladribine, methotrexate, mercaptopurine, thioguanine, capecitabine, methyltestosterone, nilutamide, testolactone, bicalutamide, flutamide, anastrozole, toremifene citrate, tamoxifen, estramustine phosphate sodium, ethinyl estradiol, estradiol, esterified estrogens, conjugated estrogens, leuprolide acetate, goserelin acetate, medroxyprogesterone acetate, megestrol acetate, levamisole HCl, aldesleukin, irinotecan HCl, dacarbazine, asparaginase, etoposide phosphate, gemcitabine HCl, trastuzumab, altretamine, topotecan HCl, hydroxyurea, interferon alfa-2b, recombinant, mitotane, procarbazine HCl, vinorelbine tartrate, *E. coli* L-asparaginase, *Erwinia* L-asparaginase, vincristine sulfate, denileukin diftitox, aldesleukin, rituximab, interferon alfa-2a, recombinant, paclitaxel, docetaxel, BCG live (intravesical), vinblastine sulfate, etoposide, tretinoin, teniposide, porfimer sodium, fluorouracil, betamethasone sodium phosphate and betamethasone acetate, letrozole, and combinations thereof.

30

24. The method of claim 1 wherein said chemotherapy agent is selected from the group consisting of etoposide, cytarabine, fluorouracil, folinic acid, calcium leucovorin, 5-fluorouracil, adriamycin, cytoxan, diamino dichloro platinum and combinations thereof.

- 5        25. The method of claim 1 wherein said side effects are selected from the group consisting of loss of appetite, loss of sleep, fatigue, reduction in daily activity, decline in overall feeling, depression, nausea and vomiting and combinations thereof.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number  
**WO 01/082949 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 38/22**,  
39/00, 38:22) (A61K 31/00, 38:22) (A61K 33/00, 38:22)  
(A61K 38/00

(21) International Application Number: PCT/US01/12696

(22) International Filing Date: 19 April 2001 (19.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/561,917 1 May 2000 (01.05.2000) US

(71) Applicant: SCICLONE PHARMACEUTICALS, INC.  
[US/US]; 901 Mariners Island Boulevard, San Mateo, CA  
94404 (US).

(72) Inventors: RUDOLPH, Alfred, R.; 14142 Liddicoat  
Drive, Los Altos Hills, CA 94022 (US). TAM, Vincent,  
Chung-Yin; 35, Ventris Road, Happy Valley, Hong Kong  
(CN). QUAN, Maggie, Jie; Room 502, No. 16, Lane 336,  
E Mei Road, Shanghai 200080 (CN).

(74) Agents: REPPER, George, R. et al.; Rothwell, Figg,  
Ernst & Manbeck, P.C., 1425 K Street, N.W., Suite 800,  
Washington, D.C. 20005 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
28 August 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/082949 A3

(54) Title: METHOD OF REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS

(57) Abstract: A method for reducing the severity of chemotherapy side effects in cancer patients by administering thymosin  $\alpha_1$  in conjunction with the administration of a chemotherapy agent to the patient. As a result of the reduction of post-chemotherapy side effects, patients experience an increase in the quality of life.

## INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/US 01/12696

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 A61K38/22 A61P39/00 //(A61K38/22,31:00),(A61K38/22,33:00),  
 (A61K38/22,38:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>E. GARACI ET AL.: "SEQUENTIAL CHEMOIMMUNOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER USING CISPLATIN, ETOPOSIDE, THYMOSIN-ALPHA1 AND INTERFERON-ALPHA2A"            EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB,            vol. 31A, no. 13/14, 1995, pages 2403-2405, XP001042211            ISSN: 0959-8049            page 2404, right-hand column, line 4 - line 12; table 2            page 2404, last paragraph</p> <p style="text-align: center;">--- -/--</p>	1-25



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \* & \* document member of the same patent family

Date of the actual completion of the international search

16 January 2002

Date of mailing of the international search report

30/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

## INTERNATIONAL SEARCH REPORT

Int. nat. Application No

PCI/US 01/12696

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	H. ISHITSUKA ET AL.: "EFFICACY OF THYMOSIN ALPHA 1 IN ANIMAL MODELS." THYMIC HORMONES AND LYMPHOKINES (PAP. ANNU. SYMP. HEALTH SCI.), 3RD (1984), - 1983 pages 425-428, XP001042188 NEW YORK, N.Y., US page 437, last paragraph; table VI page 426, last paragraph	1-25
X	G. SILECCHIA ET AL.: "EFFICACY OF REPEATED CYCLES OF CHEMO-IMMUNOTHERAPY WITH THYMOSIN ALPHA 1 AND INTERLEUKIN-2 AFTER INTRAPERITONEAL 5-FLUOROURACIL DELIVERY." CANCER IMMUNOLOGY AND IMMUNOTHERAPY, vol. 48, 1999, pages 172-178, XP002187485 BERLIN, DE page 177, right-hand column, last paragraph; tables 1,3	1-25
X	F. SALVATI ET AL.: "COMBINED TREATMENT WITH THYMOSIN-ALPHA1 AND LOW-DOSE INTERFERON-ALPHA AFTER IFOSFAMIDE IN NON-SMALL CELL LUNG CANCER: A PHASE-II CONTROLLED TRIAL" ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 16, no. 2, 1996, pages 1001-1004, XP001042209 ISSN: 0250-7005 figure 1 page 1004, right-hand column, last paragraph	1-25
X	Y. OHTA ET AL.: "THYMOSIN ALPHA1 EXERTS PROTECTIVE EFFECT AGAINST THE 5-FU INDUCED BONE MARROW TOXICITY" INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD, NY, US, vol. 7, no. 5, 1985, pages 761-768, XP001042218 ISSN: 0192-0561 page 767, right-hand column, last paragraph page 762, right-hand column, paragraph 3	1-25
A	US 527 393 A (T.W. MOODY) 28 December 1993 (1993-12-28) column 6, line 17 - line 29; claims	1-25



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/12696

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 527393	A	NONE	